Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 1.00 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.74 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.74 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.74 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.74 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.74 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.74 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614811 | 1.00 | P2RX3 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL6514561 | 1.00 | P2RX3 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861601 | 0.92 | P2RX3 (0.84) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL3318315 | 0.88 | P2RX3 (0.78) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL375601 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL375602 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL10120953 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL29381860 | 0.85 | P2RY1 (1.00) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861621 | 0.84 | P2RX3 (0.73) | P2RX3P2RY12P2RY1P2RY11ENPP1 | |
| SCHEMBL8861627 | 0.84 | P2RX3 (0.73) | P2RX3P2RY12P2RY1P2RY11ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | P2RX3 20/4885P2RY12 23/4885P2RY1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.